



Disclosures

Personal Commercial (33)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Amgen	Other - <i>Unpaid consultant</i>	None (\$0)	<i>Vascular Medicine Prevention</i>
Amgen Inc.	Other - <i>Scientific Advisory Board</i>	None (\$0)	
AstraZeneca Pharmaceuticals	Other - <i>Unpaid consultant</i>	None (\$0)	<i>Other</i>
Baim Institute	Other - <i>Unpaid Consultant</i>	None (\$0)	
Beren Therapeutics	Other - <i>Unpaid Consultant</i>	None (\$0)	
Caristo Diagnostics	Other - <i>Scientific Advisory Board</i>	None (\$0)	
Cartesian Therapeutics	Other - <i>Scientific Advisory Board</i>	None (\$0)	
CSL Behring	Other - <i>Scientific Advisory Board</i>	None (\$0)	
DalCor Pharmaceuticals	Other - <i>Scientific Advisory Board</i>	Modest (< \$5,000)	
Dewpoint Therapeutics	Other - <i>Scientific Advisory Board</i>	None (\$0)	
Esperion Therapeutics	Other - <i>Unpaid consultant</i>	None (\$0)	<i>Vascular Medicine</i>
Eulucid Bioimaging	Other - <i>Unpaid Scientific Advisory Board Member</i>	None (\$0)	<i>Prevention</i>
Genentech	Other - <i>Unpaid Consultant</i>	None (\$0)	
Kancera	Other - <i>Unpaid Consultant</i>	None (\$0)	
Kowa Pharmaceuticals	Other - <i>Scientific Advisory Board</i>	None (\$0)	
Medimmune	Other - <i>unpaid consultant</i>	None (\$0)	<i>Other</i>
Medimmune, Inc	Other - <i>scientific advisory board</i>	None (\$0)	
Merck & Co., Inc.	Other - <i>Unpaid Consultant</i>	None (\$0)	
Moderna	Other - <i>Unpaid Scientific Board Advisory Member</i>	None (\$0)	<i>Vascular Medicine</i>
Novartis	Research/Research Grants	Significant (>= \$5,000)	<i>Vascular Medicine</i>
Novartis	Other - <i>Unpaid consultant</i>	None (\$0)	<i>General Cardiology Prevention</i> <i>Vascular Medicine</i>
Novartis Corporation	Other - <i>Scientific Advisory Board Member</i>	None (\$0)	<i>Other</i>
Novo Nordisk Inc.	Other - <i>Unpaid Consultant</i>	None (\$0)	
Olatec Therapeutics	Other - <i>scientific advisory board member</i>	None (\$0)	
Pfizer	Other - <i>Unpaid consultant</i>	None (\$0)	<i>Vascular Medicine Prevention</i>
PlaqueTec	Consultant Fees/Honoraria	None (\$0)	
Sanofi-Regeneron	Other - <i>Unpaid consultant</i>	None (\$0)	<i>Acute Coronary Syndromes</i>
Soley Therapeutics	Other - <i>PL has financial interest in Soley, which combines AI with molecular and cellular response detection for discovering and developing new drugs, currently focusing on cancer therapeutics.</i>	None (\$0)	<i>Prevention</i>
Soley Therapeutics	Other - <i>Unpaid Scientific Advisory Board member</i>	None (\$0)	<i>Prevention</i>
TenSixteen Bio	Other - <i>Dr. Libby has financial interest in TenSixteen Bio, a company targeting CHIP to discover and develop novel therapeutics to treat age-related diseases.</i>	None (\$0)	<i>Prevention</i>
TenSixteen Bio	Other - <i>Scientific Advisory Board</i>	None (\$0)	
XBioTech Inc	Other - <i>scientific advisory board member; Dr. Libby is on the Board of Directors.</i>	None (\$0)	

Company Name	Relationship Category	Compensation Level	Topic Area(s)
XBiotech, Inc., TenSixteen Bio, Soley Therapeutics	Other - Dr. Libby's interests were reviewed and are managed by Brigham and Women's Hospital and Mass General Brigham in accordance with their conflict-of-interest policies.	None (\$0)	Prevention

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (1)

Funding Source	Institutional Compensation Level
Multiple Pharma, Device	None (\$0)

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 11/3/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 11/3/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 11/3/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 11/3/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.